• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Abeona Therapeutics Inc.

    5/15/24 4:31:31 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on May 15, 2024.

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Abeona Therapeutics Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   83-0221517
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

     

    6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Amended and Restated Abeona Therapeutics Inc.

    2023 Equity Incentive Plan

    (Full title of the plan)

     

    Joseph Vazzano

    Chief Financial Officer

    Abeona Therapeutics Inc.

    6555 Carnegie Ave, 4th Floor

    Cleveland, OH 44103

    (646) 813-4701

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies of Correspondence to:

     

    Sean M. Ewen, Esq.
    Jared N. Fertman, Esq.
    Willkie Farr & Gallagher LLP

    787 Seventh Avenue
    New York, NY 10019-6099

    (212) 728-8000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Abeona Therapeutics Inc. (the “Registrant”) to register an additional 1,500,000 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), issuable under the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (the “Plan”), which was amended and restated on March 15, 2024 to increase the number of shares of Common Stock reserved for issuance thereunder, which amendment and restatement has been approved by the Registrant’s shareholders.

     

    Pursuant to the Registration Statement on Form S-8 (Registration No. 333-272103) filed by the Registrant on May 19, 2023 (the “Prior Registration Statement”), the Registrant previously registered an aggregate of 1,700,000 shares of Common Stock. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statement and represent an increase in the total shares available for issuance under the Plan by 1,500,000. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference into this Registration Statement the contents of the Prior Registration Statement, including all exhibits filed therewith or incorporated therein by reference, except as expressly modified herein.

     

    -2-
     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Abeona Therapeutics Inc. (the “Company” or “Registrant”) with the Securities and Exchange Commission (the “Commission”) are hereby incorporated by reference into this Registration Statement:

     

    (i)The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (filed with the Commission on March 18, 2024);

     

    (ii)The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 (filed with the Commission on May 15, 2024);

     

    (iii)The Company’s Current Reports on Form 8-K filed with the Commission on April 22, 2024, April 24, 2024 and May 3, 2024 (film numbers 24910733 and 24914408) and

     

    (iv)The description of our common stock, par value $0.01 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November 4, 2014, as updated by Exhibit 4.4 to our Form 10-K for the fiscal year ended December 31, 2019, and including any amendments or reports filed with the SEC for the purpose of updating such description.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    All reports and other documents that the Company subsequently files with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that the Company has sold all of the securities offered under this Registration Statement or deregisters the distribution of all such securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date that the Company files such report or document.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    -3-
     

     

    Item 8. Exhibits.

     

    A list of exhibits filed herewith is contained in the Exhibit Index below, which is incorporated herein by reference.

     

    EXHIBIT INDEX

     

            Incorporated by Reference    
    Exhibit No.   Description   Form   File No.   Exhibit   Filing Date   Filed Herewith
    4.1   Restated Certificate of Incorporation of Abeona Therapeutics Inc.   10-Q   001-15771   3.1   May 10, 2019    
    4.2   Certificate of Amendment to Restated Certificate of Incorporation of Abeona Therapeutics Inc.   8-K   001-15771   3.1   June 30, 2022    
    4.3   Amended and Restated Bylaws of Abeona Therapeutics Inc.   10-K   001-15771   3.3   March 29, 2023    
    5.1   Opinion of Willkie Farr & Gallagher LLP                   X
    23.1   Consent of Whitley Penn LLP                   X
    23.2   Consent of Deloitte & Touche LLP                   X
    23.3   Consent of Willkie Farr & Gallagher LLP (included in Exhibit 5.1 hereto)                   X
    24.1   Powers of Attorney (included in the signature page of this Registration Statement)                   X
    99.1   Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan   DEF 14A   001-15771   Appendix A   March 19, 2024    
    107   Filing Fee Table                   X

     

    -4-
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morristown, in the state of New Jersey, on the 15th day of May, 2024.

     

    ABEONA THERAPEUTICS INC.  
         
    By: /s/ Joseph Vazzano  
      Joseph Vazzano  
      Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)  

     

    -5-
     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby appoints Vishwas Seshadri and Joseph Vazzano and each of them, severally, as his or her true and lawful attorney or attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and dates indicated.

     

    Signature   Title   Date
             
    /s/ Vishwas Seshadri   President, Chief Executive Officer and Director (Principal Executive Officer)   May 15, 2024
    Vishwas Seshadri        
             
    /s/ Joseph Vazzano   Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)   May 15, 2024
    Joseph Vazzano        
             
    /s/ Leila Alland   Director   May 15, 2024
    Leila Alland        
             
    /s/ Mark Alvino   Director   May 15, 2024
    Mark Alvino        
             
    /s/ Michael Amoroso   Director   May 15, 2024
    Michael Amoroso        
             
    /s/ Faith Charles   Director   May 15, 2024
    Faith Charles        
             
    /s/ Christine Silverstein   Director   May 15, 2024
    Christine Silverstein        
             
    /s/ Donald Wuchterl   Director   May 15, 2024
    Donald Wuchterl        

     

    -6-

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO

    DatePrice TargetRatingAnalyst
    6/2/2025$19.00Outperform
    Oppenheimer
    3/5/2025$16.00Outperform
    Oppenheimer
    7/3/2024$15.00Buy
    H.C. Wainwright
    5/30/2024$21.00Buy
    Stifel
    11/30/2021$5.00 → $1.00Outperform → Market Perform
    SVB Leerink
    11/29/2021$5.00 → $4.00Buy
    HC Wainwright & Co.
    7/19/2021$8.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ABEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On January 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 28,676 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that t

    2/9/26 10:04:41 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 30, 2025, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 79,584 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Da

    12/31/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

    CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. "Mohamad brings a wealth of experience in strategic planning and business development," said Vish Seshadri, Chief Executive Officer of Abeona. "We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships." Mr. Tabrizi transitions to Abeon

    12/15/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Silverstein Christine Berni sold $102,168 worth of shares (20,070 units at $5.09), decreasing direct ownership by 13% to 137,722 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    2/4/26 4:30:06 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wuchterl Donald A. sold $75,412 worth of shares (14,814 units at $5.09), decreasing direct ownership by 8% to 167,935 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    2/2/26 6:59:29 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Crombez Eric sold $82,895 worth of shares (16,284 units at $5.09), decreasing direct ownership by 20% to 63,456 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    2/2/26 6:55:32 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Abeona Therapeutics with a new price target

    Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00

    3/5/25 7:50:58 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Abeona Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00

    7/3/24 7:23:46 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Alland Leila bought $51,799 worth of shares (11,000 units at $4.71), increasing direct ownership by 15% to 82,857 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    5/20/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seshadri Vishwas bought $32,000 worth of shares (10,000 units at $3.20), increasing direct ownership by 2% to 538,260 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Charles Faith L. bought $24,764 worth of shares (7,550 units at $3.28), increasing direct ownership by 11% to 78,323 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    SEC Filings

    View All

    SEC Form 144 filed by Abeona Therapeutics Inc.

    144 - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    1/21/26 4:10:24 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Abeona Therapeutics Inc.

    10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    11/12/25 7:35:53 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    11/12/25 7:30:28 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Leadership Updates

    Live Leadership Updates

    View All

    Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

    CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. "Mohamad brings a wealth of experience in strategic planning and business development," said Vish Seshadri, Chief Executive Officer of Abeona. "We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships." Mr. Tabrizi transitions to Abeon

    12/15/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

    CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."

    10/20/25 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

    CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders. Michael Amoroso, Chairman of Abeon

    8/14/24 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

    - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs

    11/12/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

    CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 877-545-0523 (U.S. toll-free) or 973-528-0016 (international) and Entry Code: 922481 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available

    11/7/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

    - Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage established with multiple national and regional payers - - $226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginn

    8/14/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    10/8/24 4:29:58 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abeona Therapeutics Inc. (Amendment)

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    6/3/24 4:30:14 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care